Alvotech Swiss AG
20
1
1
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
5.0%
1 terminated/withdrawn out of 20 trials
94.4%
+7.9% vs industry average
50%
10 trials in Phase 3/4
18%
3 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Role: lead
A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Role: lead
Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
Role: lead
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
Role: lead
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
Role: lead
A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants
Role: lead
AVT03 With Xgeva in Healthy Male Subjects
Role: lead
Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease
Role: lead
Pilot Study of AVT16 in Healthy Adult Subjects
Role: lead
Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX
Role: lead
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
Role: lead
AVT03 With Prolia in Healthy Male Subjects
Role: lead
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Role: lead
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
Role: lead
Auto-injector Real Life Handling in Patients
Role: lead
Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
Role: lead
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)
Role: lead
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Role: lead
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Role: lead
Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers
Role: lead
All 20 trials loaded